Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experiences with methyldopa.

A C Pessina, R Pigato, C D Palù

    Clinical and Experimental Pharmacology & Physiology. Supplement
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study.

    Nutrition, metabolism, and cardiovascular diseases : NMCD·2014
    Same author

    Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design.

    Journal of human hypertension·2012
    Same author

    The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design.

    Journal of human hypertension·2011
    Same author

    Glycaemic fall after a glucose load. A population-based study.

    Nutrition, metabolism, and cardiovascular diseases : NMCD·2009
    Same author

    Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity.

    Journal of endocrinological investigation·2009
    Same author

    High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?

    Journal of endocrinological investigation·2009

    Methyldopa effectively lowers blood pressure in patients with mild, moderate, and severe hypertension. This hypotensive drug showed minimal impact on kidney function and did not cause serious ischemic events.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Background:

    • Hypertension is a prevalent cardiovascular condition requiring effective pharmacologic management.
    • Methyldopa is an established antihypertensive agent with a known safety profile.

    Purpose of the Study:

    • To evaluate the efficacy and safety of methyldopa in a diverse patient population with varying degrees of hypertension.
    • To assess the impact of methyldopa on renal function markers (BUN and serum creatinine) and ischemic events.

    Main Methods:

    • A study involving 155 patients with hypertension.
    • Treatment involved methyldopa, administered alone or in combination with other hypotensive medications.
    • Blood pressure, BUN, serum creatinine, and incidence of orthostatic hypotension and ischemic symptoms were monitored.

    Related Experiment Videos

    Main Results:

    • Blood pressure normalized in 80% of mild and 50% of moderate hypertension cases within 10 days.
    • Significant blood pressure reduction was observed in severe hypertension.
    • No significant increase in BUN or serum creatinine was noted, unlike other hypotensive drugs.
    • Orthostatic hypotension occurred in 18% of patients without significant cerebral or myocardial ischemia.

    Conclusions:

    • Methyldopa demonstrates significant hypotensive efficacy across the spectrum of hypertension severity.
    • Methyldopa exhibits a favorable renal safety profile compared to other antihypertensives.
    • The drug is well-tolerated, with manageable side effects and a low risk of serious ischemic complications.